Cannabis use may hinder conception efforts
Marijuana use may make conception more difficult for women who smoke than those who don’t, according to a prospective cohort study from the National Institutes of Health (NIH).
The prospective cohort study focused on cannabis use via urinary metabolites and self-reporting during preconception, and whether it was associated with fecundability, live birth, and pregnancy loss. The findings, published in Human Reproduction, linked preconception cannabis use with reduced fecundability despite increased frequency of intercourse.1
The study evaluated 1,228 women aged 18 to 40 years with a history of pregnancy loss. The women were followed up with from 2006 to 2012 for up to 6 cycles while attempting pregnancy, and throughout pregnancy if they conceived. Self-reported preconception cannabis use and urinary tetrahydrocannabinol metabolites were recorded at baseline, after 6 months of follow-up or at the beginning of the conception cycle, and weeks 4 and 8 of pregnancy.
Researchers concluded that women with preconception cannabis use did have reduced fecundability (FOR 0.59; 95% CI 0.38, 0.92). They also found associations, although imprecise, with anovulation (RR 1.92, 95% CI 0.88, 4.18) and live birth (42% (19/45) cannabis users versus 55% (578/1043) nonusers; RR 0.80, 95% CI 0.57, 1.12). They did not find any association with preconception cannabis use and pregnancy loss (RR 0.81, 95% CI 0.46, 1.42).
__
Reference
- S L Mumford, K S Flannagan, J G Radoc, L A Sjaarda, et al, Cannabis use while trying to conceive: a prospective cohort study evaluating associations with fecundability, live birth and pregnancy loss, Human Reproduction, deaa355, https://doi.org/10.1093/humrep/deaa355
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More
